ABSTRACT In 11 asthmatic subjects the relative magnitude and the site of airway bronchoconstriction were compared after the oral administration of 40 mg of propranolol and 2-5 mg of pindolol and the magnitude and site of bronchodilation produced by 0*5 mg subcutaneous terbutaline were tested after pretreatment with propranolol and pindolol. Specific airway conductance (sGaw) and peak expiratory flow rate (PEFR), both believed to reflect changes in large airways, and capacity isoflow (Ciso-v) and AVmax50, both believed to reflect changes in small airways, were determined before and after administration of placebo, pindolol, and propranolol. Treatments were given double blind and in random order. After the administration of propranolol we noted a significant bronchoconstrictive effect in the large airways (mean values of PEFR and sGaw, expressed as percentages of control values, decreased by 87*4% + 13-2% and 43.3% + 8-9%) and in the small airways (mean value of Ciso-v increased by 20-6% + 4-7% and that of AVmax5O decreased by 50% + 11.9% of control). By contrast, pindolol produced no significant effect on sGaw or PEFR but the tests of small airway function showed significant bronchoconstriction (mean values of Ciso-v increased by 12*9% + 2.6% and those of AVmax,0 decreased by 47-2% + 9.2%). This action makes pindolol potentially dangerous in asthmatic patients. The bronchodilator action of terbutaline on large airways is diminished after the use of both propranolol and pindolol.
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Information on the effects of f8-adrenergic blocking drugs on respiratory function tests in asthmatic subjects has been reported,'-3 but so far little information is available on the effects of /3-adrenergic blocking drugs on the results of tests believed to reflect small airway function.
Bronchodilation is mediated through catecholamine stimulation of the ,82-receptors in the lung and S-adrenergic-blocking drugs can precipitate bronchoconstriction. It is generally believed that intrinsic sympathetic activity is desirable in a betablocker that has to be given to a patient prone to bronchoconstriction.45 Non-selective ,8-adrenergic blockers, with or without intrinsic sympathetic activity, may lessen the bronchodilator effect of 12-stimulants.6 This study was designed to compare the effects of oral propranolol (a drug with practically no intrinsic sympathetic activity) and pindolol (a drug with high intrinsic sympathetic activity) on large and small airways and to examine the bronchodilator effect of Address for reprint requests: Dr Demetrios Patakas, 1 Patriarchou loakim Street, Thessaloniki, Greece. terbutaline in asthmatic patients previously treated with propranolol or pindolol.
Methods
Eleven asthmatic subjects (four male, seven female) were studied after giving informed consent. The subjects were all adults (mean age in years 31 + 8 SD) with asthma as defined by Scadding;7 the mean duration of asthma was 7 ± 3-4 SD years. All had a baseline FEVI which was less than 70% of the predicted normal value8 (mean 45-7 ± 15- Vmax50(He-02-Vmax50 (air).
Vmax 0 air
The absolute volume of isoflow (Viso-') was calculated as the quantity between residual volume and the volume at which the He-02 and air curves first coincide.'2 The sum of the absolute Viso-v and residual volume was expressed as a percentage of the total lung capacity to obtain the capacity of isoflow (Ciso-v) .'3 Ciso-v takes into account changes in both residual volume (which would be expected to increase if obstruction in peripheral airways leading to trapping were made worse by treatment with a beta-blocker) and the volume of isoflow (which would also be increased if equal pressure points moved into small airways as a result of increase of airflow resistance in small airways).
The study was conducted on three separate days at least 48 hours apart. On the study day the subjects were under medical supervision for 24 hours. Early in the morning subjects underwent a control pulmonary function test consisting of whole-body plethysmography followed by timed spirometry, measurement of PEFR, and construction of maximal expiratory flow-volume curves obtained with subjects breathing air and the He-02 mixture. After completing the control studies the subjects were given a coded tablet (double blind) containing placebo, propranolol 40 mg, or pindolol 2.5 mg. The order of the treatments was randomly distributed. Peak flow rate measurements and standing heart rate counts were made every 30 minutes in the first three hours, and hourly for the following three hours. Pulmonary function tests were repeated two hours after administration of the drug, as peak concentrations in the blood and maximal beta-blockade are known to occur at about this time. Subsequently 0-5 mg of terbutaline was given subcutaneously and 30 minutes later the pulmonary function tests were repeated.
The effect of drug treatment on the density dependence of flow was measured in two ways: (1) as the difference between AlVmax50 measured before (control values) and after beta-blocking treatment and after the administration of terbutaline and expressed as percentage of the control value; (2) as the difference between Ciso-v before and after beta-blocking treatment and after administration of terbutaline-this was also expressed as a percentage of the control value. The effect of drug treatment on large airway function was similarly obtained from changes in sGaw and PEFR.
Parametric data were analysed by Student's t test for paired data. A significant difference was assumed to exist for probability values < 0-05.
Results
The mean standing pulse rate before the administration of propranolol was 81-2 + 5 3 beats/min and it dropped two hours after administration of propranolol to 62 5 + 4 1; 30 minutes after subcutaneous terbutaline it was 63 ± 3-9 beats/min. The mean standing pulse rate before pindolol was 79 5 ± 4-5 per minute. It decreased after pindolol to 67-3 ± 3-8 beats/min and remained unchanged after subcutaneous terbutaline (68.0 + 4.2 beats/min). Com- paring the changes in heart rate after propranolol and pindolol we found no significant differences.
CONTROL PULMONARY FUNCTION
There were no statistically significant differences between the placebo, propranolol, and pindolol days The mean percentage increases in sGaw and PEFR were significantly greater (p < 0-01 and p < 0-001 respectively) when terbutaline was administered after placebo than after propranolol. The mean percentage increases in sGaw and PEFR were both significantly greater (p < 0-01) when terbutaline followed placebo than when it followed pindolol.
Ciso-v decreased after terbutaline administration and increased when terbutaline was given after propranolol or pindolol. These changes were in AlVmaxso values were not significantly greater when terbutaline followed placebo than when it followed propranolol or pindolol. An increase in FRC and RV-that was produced by the administration of terbutaline after pindolol or propranolol was not significantly different from the FRC and RV changes that occurred when terbutaline was given after placebo.
Although increases in large and small airway resistance were recorded, no patient reported a major change in breathing after taking betablockers.
Discussion
The standing pulse rate was chosen to assess betablockade since this is influenced more by sympathetic and less by vagal discharge than is the supine pulse rate.14 There was a mean decrease of about 19 beats per minute during propranolol treatment and about 12 beats per minute during pindolol treatment; it is difficult to judge whether the difference is due to a relatively higher dosage of propranolol or to the intrinsic sympathetic activity of pindolol. The doses of the drugs were chosen on the basis of accepted beta-blocking potency ratios in man and also because they were close to dosage levels used in clinical practice. '5 Propranolol reduced sGaw and peak expiratory flow rate significantly but pindolol did not. The significantly greater deterioration in functional indices reflecting changes in large airway calibre after propranolol than after a beta-blocker with high intrinsic sympathetic activity has been referred to by others.316 Although the helium isoflow volume and the ratio of MEFR with helium to MEFR with air are very poorly reproducible in normal subjects, '7 the deterioration in Ciso-v and AVmax,0 after pindolol and propranolol in the present study was combined with a significant increse in FRC and RV. This is probably another manifestation of the degree of obstruction within the distal bronchi. Tests of small airway function seem to be required to identify the bronchoconstrictive effect of pindolol in asthmatic subjects.
Terbutaline's bronchodilating effect on large airways was significantly diminished when patients were pretreated with a single dose of propranolol br pindolol. It is difficult to comment on the effect of terbutaline in small airways of patients pretreated with a single dose of propranolol or pindolol since only the Ciso-v changes were significant.
Although pindolol has a high intrinsic sympathetic activity and has no detectable effect on the results of tests of large airway obstruction, it has a bronchoconstrictive effect on small airways similar to that of propranolol and thus may not be safe for the asthmatic patient. 
